| 1998 | | Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide. | 김영수, 김진홍, 이광재, 임현이, 조성원, 주희재, 함기백 |
| 2003 | | Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible? | 김명욱, 김영배, 김진홍, 유병무, 조성원, 한상욱, 함기백 |
| 2015 | | Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials. | 신승수 |
| 2003 | | Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. | 김진홍, 유병무, 이기명, 조성원, 주희재, 함기백 |
| 1998 | | Helicobacter pylori infection, oxidative DNA damage, gastric carcinogenesis, and reversibility by rebamipide. | 김진홍, 이광재, 조성원, 함기백 |
| 2014 | | Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy. | 추설호 |
| 2014 | | Novel synthetic protective compound, KR-22335, against cisplatin-induced auditory cell death. | 강성운, 김철호, 신유섭 |
| 2011 | | Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea. | 이위교 |
| 2004 | | Preventive effect of the flavonoid, wogonin, against ethanol-induced gastric mucosal damage in rats. | 함기백 |
| 1998 | | Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. | 김영수, 김진홍, 이광재, 임현이, 조성원, 주희재, 함기백 |
| 2019 | | Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains | 김용찬, 김은진 |
| 1997 | | Role of rebamipide on induction of heat-shock proteins and protection against reactive oxygen metabolite-mediated cell damage in cultured gastric mucosal cells. | 김영수, 김진홍, 윤정구, 조성원, 함기백 |
| 2024 | | Safety outcomes of antipsychotics classes in drug-naïve patients with first-episode schizophrenia: A nationwide cohort study in South Korea | 박래웅 |
